Dr. Frederick Sancilio reports

LOBE SCIENCES APPOINTS ANNETTE GRIMALDI, FORMER HEAD OF LIFE SCIENCES INVESTMENT BANKING AT BMO CAPITAL MARKETS, TO BOARD OF DIRECTORS

Lobe Sciences Ltd. has appointed Annette Grimaldi to its board of directors.

Ms. Grimaldi is a veteran life sciences investment banker with 35 years of experience advising chief executive officers, chief financial officers, and boards on public and private financings, mergers and acquisitions, and strategic transactions. From 2009 to 2024, she established, built and led the life sciences practice at BMO Capital Markets as managing director and head of life sciences investment banking. She previously established and led the life sciences investment banking practice at Jefferies & Company, served as managing director in health care investment banking at SG Cowen Securities Corp., and began her career at Goldman, Sachs & Co. in New York and Tokyo.

"At Goldman Sachs, Annette was an integral part of my first IPO, and I saw firsthand how her judgment, investor relationships and command of the capital markets can help a company reach its goals," said Dr. Frederick D. Sancilio, PhD, chairman and chief executive officer of Lobe Sciences. "As we advance L-130 in anxiety and cluster headache and S-100 in sickle cell disease, her decades of experience financing and partnering life sciences companies, together with her relationships across the investor community, will be invaluable. I am delighted to welcome Annette to the board and look forward to working with her again."

Ms. Grimaldi currently serves on the board of Delsona Therapeutics, is a venture adviser to Pontiva Healthcare Partners, and is a founding member of Extraordinary Women on Boards (EWOB). She holds an MBA from the Wharton School and a master of international studies from the Lauder Institute at the University of Pennsylvania, and a bachelor of science in foreign service, Summa Cum Laude and Phi Beta Kappa, from Georgetown University.

In connection with her appointment, Ms. Grimaldi was granted four million restricted share units of the company, in accordance with the company's equity incentive plan and applicable regulatory requirements.

About Lobe Sciences Ltd.

Lobe Sciences is a clinical-stage biopharmaceutical company developing therapies for diseases with unmet medical needs. Through its majority-owned subsidiary Cynaptec Pharmaceuticals, Inc., the company is developing L-130 (psilocin mucate), a patented, stable oral form of psilocin being investigated for generalized anxiety disorder, cluster headache, and other neurological and psychiatric conditions. Its wholly owned subsidiary Applied Lipid Technologies Inc. is developing S-100, an investigational new drug for the treatment of sickle cell disease. Lobe directs and oversees research and development through a global network of manufacturing, preclinical and clinical service providers.

We seek Safe Harbor.